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106 /kg recipient weight. All patients engrafted rapidly at
a median rate of 15 days for neutrophils and 16 days for
platelets. Although the total incidence of cGVHD was 43%,
only 17% had extensive cGVHD, and the remaining 26% had
the limited form which was very well controlled under
a small-dose of immuno-suppressive therapy. By sub-group
analysis, we found that the vast majority of patients with
extensive cGVHD received the initial lower dose of Flu (75mg/
m2), and half of them were >30 years old. Since then, we've
standardized the dose to be 120mg/m2. At a follow up period
of up to 9 years (median 5.9 years), both DFS &OSwere 79.2%.
Conclusion: Allografting SAA patients with PBSCs, using the
Flu-Cy regimen has a signiﬁcantly lower cost, with excellent
tolerability, andpromisingoutcomeregardingengraftment,DFS
& OS. The incidence of cGVHD can be considered acceptable,
putting in mind the higher patients’ age and the initial lower
dose of Flu that we've used. However, this approach deﬁnitely
needs a larger cohort of patients to be randomly compared to
the standard Cy-ATG regimenwith the use of BM cells.357
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Allogeneic hematopoietic cell transplantation (Allo-
HSCT) has proven to have curative potential for myelodys-
plastic syndrome (MDS). However, relapse post HSCT
continues to be a problem. Pre-HSCT cytoreduction with
either intensive chemotherapy or hypomethylating agents
has been used with limited data on pre- or post-HSCT
outcomes. In this report, we evaluated the impact of pre-
transplant therapy on post-HSCT outcomes including overall
survival (OS) and Progression Free Survival (PFS).
Methods: We retrospectively reviewed 31 patients who
underwent allo-HSCT forMDS in our center between 1997 and
2012.Primaryobjectivewas to study the impactof therapypre-
HSCT on HSCT outcome. Demographics, disease-related and
transplant-relatedvariableswere collected. PFSwasdeﬁned as
the time from HSCT to the time of progression, death or last
contact whichever occurred ﬁrst. OS was deﬁned as the time
fromHSCTto the timeofdeathor last contact. Thedistributions
of PFS and OS were estimated by the Kaplan-Meier method.
The log-rank test was used to compare the survival distribu-
tions between the twogroups. Regression analyses for survival
data used Cox proportional hazards model.
Results:Median age at HSCT was 58 years. Median time from
diagnosis to HSCTwas 145 days. Of the 31 patients, 38.8% had
poor cytogenetic abnormalities. Conditioning regimen used
was high-dose in 71% or a reduced-intensity in 29%. 18/31
patients (58.1%) received therapy before HSCT. Intensive
therapy with cytarabine was used in 3 patients while non-
intensive therapy, with hypomethylating agents, median of 4
cycles, were used in 11 patients, Thalidomide or Lenalido-
mide in 3 patients and hydroxyurea in 1.13/31 (41.9%) did not
get any therapy prior to HSCT.
On univariate analysis, the treatment prior to HSCT had
adverse impact on PFS and OS (HR¼2.8, P ¼ .0404 and
HR¼2.8, P ¼ .0387 respectively). In multivariate models,
treatment prior to HSCT still emerged as a signiﬁcant
predictor of poor PFS and OS (HR¼6.6, P¼ .0070 and HR¼8.1,P¼ .0037 respectively) after adjusting for age, gender andWHO
classiﬁcation-based Prognostic Scoring System. There was no
statistical signiﬁcant difference in the change inpercentage of
blasts at diagnosis and just before transplant for those who
received therapy compared to those who did not (P ¼ .5496).
Conclusion: In this small cohort from a single center, the
results are not in favorofMDSpatients receiving therapyprior
to HSCT. Prospective study with larger cohort should be
conducted to address this issue and taking into consideration
disease characteristics in patients who may and may not
beneﬁt from pre-transplant therapy. As recently published
approximately 85% of bone marrow cells are clonal in MDS
regardless of blast count (Walter et al. NEJM 2012)whichmay
explain our result of no difference in blast percentage before
or after therapy and should not be used as a surrogatemarker.358
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Background: Invasive pulmonary aspergillosis (IPA) remains
a signiﬁcant cause of infectious morbidity and mortality in
hematopoietic cell transplant (HCT) recipients. The serum
and BAL galactomannan (GM) index are widely used myco-
logic criteria for the diagnosis of IPA; however, their prog-
nostic value at the time of diagnosis is poorly deﬁned. It
remains unclear whether IPA patients with a positive serum
or BAL GM index have different clinical outcomes than IPA
patients with a negative GM index in the corresponding
compartment, and whether higher GM index cut-off levels
correlate with poor outcome. In this study, we examined the
prognostic value of quantitative aspects of both the serum
and BAL GM index at the time of IPA diagnosis.
Methods: We retrospectively analyzed a cohort of 100 adult
patients with probable IPA (per 2008 revised EORTC criteria)
diagnosed in 2004-2010 within 100 days after a ﬁrst allo-
geneic HCT. All subjects had a chest CT, a serum GM, and
a BAL GM index performed at the time of IPA diagnosis. We
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Figure 1. Kaplan Meier survival curve of different magnitudes of serum GM
indices (A), and BAL GM indices (B)
Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312 S289evaluated the impact of different GM cut-off levels in serum
and BAL on mortality. Kaplan Meier curves were used to
estimate survival, and Cox proportional hazardsmodels were
used to evaluate univariate and adjusted hazards ratios for
180 day all-cause mortality associated with different serum
and BAL GM index cutoff values.
Results: A diagnosis of probable IPA was made by a positive
serumGMindex (0.5) alone in32patients andapositiveBAL
GM index (0.5) alone in47patients. In 21patients, the serum
andBALGMindiceswerebothpositive.Overallmortality in all
patients was 52% at 180 days. Patients with a positive serum
GM index at the time of IPA diagnosis had an increased
mortality (60.4%; n ¼ 53) compared to patients with a nega-
tive serum GM index (42.6%; n ¼ 47). In contrast, a positive
BAL GM index had no effect on mortality (Figure 1A,B). In
addition, the magnitude of the serum GM index was associ-
ated with enhanced mortality. When compared to a serum
GM index of  0.5, increasing values of serum GM were
associated with an increased HR of 180 day mortality (serum
GM  1: HR ¼ 2.18 (1.15-4.15); serum GM  1.5: HR ¼ 2.97
(1.53-5.81); serumGM 2: HR¼ 3.68 (1.63-8.30)). This result
was conﬁrmed in a multivariate analysis that adjusted for
acute GVHD, sex, underlying hematologic disease severity,
and elevated creatinine. No association was seen with
increasing magnitudes of BAL GM indices.
Conclusions: This study shows an increased HR for mortality
with increasing cutoffs of serum GM indices, with no corre-
sponding increase in HR with increasing BAL GM indices. We
propose that the initial serum GM index value at the time of
IPA diagnosis represents both an important prognostic
indicator and a valuable covariate in future analyses on
outcomes in HCT recipients.359
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Background: Phase II studies suggested that pts who
received an in-vivo T-cell depleted (TCD) alloSCT with
Alemtuzumab (AL) tended to have less aGVHD.However, the
utility of this approach is limited by increased incidence ofmixed chimerismwhich is associated with increased disease
recurrence and often require DLI.
Hypothesis:We hypothesize that sub-optimal CD 34 +ve cell
dose contribute to mixed chimerism after an in-vivo TCD
alloSCT using AL. By identiﬁng an optimal CD 34 +ve cell
dose; an in-vivo TCD protocol could maintain the beneﬁt of
lowering the incidences of GVHD and minimize mixed
chimerism. We also evaluate other patient & treatment
characteristics that may contribute to mixed chimerism.
Method: We conducted a retrospective study to evaluate the
impact of CD 34 +ve cell dose and patient and treatment
characteristics on T-cell and Myeloid chimerism after an in-
vivo TCD alloSCT. Between 5/11 & 5/12, 32 consecutive pts
underwent an in-vivo TCD alloSCT. F/M: 18/14. The diagnosis
included 21 AML/MDS, 4 NHL, 3 MDS & 7 others. Conditioning
regimensconsistedofFludarabine/Melphalan:22, Fludarabine/
Busulfan: 7 and others in 3. Upon achievement of engraftment,
wemonitorengraftmentbyShort tandemrepeatmonthlywith
T-cell andMyeloid subsets analysis.We utilize of AL for in-vivo
TCD (20MRD: 30mgonDay -1; 12MUD: 30mgdaily onDay -2
& Day -1). All patients also received cyclosporine.
Results: Pts received a median of 4.96 x 10e6 per kg CD 34
positive cells (range 2.45 e 27.22). 30/32 pts achieved
neutrophils engraftment except 1 died shortly after SCT from
CHF & 1 experienced primary graft failure with day 30 STR
showing only 3% donor T-cell chimerism. On Day 30 post-
SCT, all evaluable pts had predominately donor T-cell
(median 99%; 22/31 (71%)  99%; range 82 to > 99%) and
Myeloid Chimerism (28/31 (90%)  99%. 25 pts survived
beyond Day 90 and have engraftment data available for
analysis . Between Days 90 & 120 analysis, most pts maintain
predominant donor myeloid chimerism (> 95%; median
99%); only 11/25 (44%) had maintained  91% donor T-cell
chimerism. 7/25 (28%) and 7/25 (28%) had 71-90 % and 70%
donor T-cell chimerism respectively. CD 34 +ve Cell dose,
disease type, disease status, prior treatment, age, sources of
stem cells (MRD vs MUD) and conditioning regimen did not
predict for mixed chimerism. While 43% of the patients
received Melphalan/Fludarabine; 60% of the patients
received a busulfan/ﬂudarbine had donor T-cell chimerism
dropped below 80% between day 90-120. Five pts (17%)
developed acute GVHD with only 1 (4%) Grade IV aGVHD.
Conclusion: 1. Mixed chimerism is common after in-vivo
TCD alloSCT; 2. CD 34 Cell dose, disease type, prior treatment,
age, sources of stem cells and conditioning regimen did not
predict for mixed chimerism & 3.The high incidences of
signiﬁcant mixed chimerism (< 80%) on day 90 in pts
received Bu/Flu is of concerns that warrant close monitoring
in future studies.360
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